<DOC>
	<DOC>NCT03091920</DOC>
	<brief_summary>To compare the safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects of 2 treatment regimens of IW-1973 Tablet (40 mg per day) administered orally for 2 weeks to patients with stable type 2 diabetes mellitus and hypertension.</brief_summary>
	<brief_title>Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patient is ambulatory male or female Patient's body mass index score is &gt;20 and &lt;40 kg/m2 at the Screening Visit Women of childbearing potential must have a negative pregnancy test at the time of screening and checkin and must agree to use protocolspecified contraception throughout the duration of the study Patient's health is stable with no clinically significant findings on physical examination Patient has type 2 (ie, adult onset) diabetes mellitus diagnosed by a physician or nurse practitioner &gt; 6 months before the Screening Visit, is on a stable glycemic control medication, and protocol specified HbA1c values at the Screening Visit Patient has hypertension diagnosed by a physician or nurse practitioner &gt; 6 months before the Screening Visit, and BP within the protocol's acceptable range Patients must be on a stable regimen for hypertension control that includes an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) Other inclusion criteria per protocol Patient has a clinically significant active or unstable medical condition that, in the opinion of the Investigator, would preclude trial participation Patient is on medication(s) that, when coadministered with a soluble guanylate cyclase (sGC) stimulator, could increase the risk of hypotension Patient has evidence of severe or active endorgan damage Patient is an active smoker or has used any nicotinecontaining products (cigarettes, ecigarettes, vape pens, cigars, chewing tobacco, gum, patches) during the 6 months before Checkin. Use of nicotine is excluded during the study until after the End of Trial Visit. Other exclusion criteria per protocol</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>